COSCIENS Biopharma Inc. (CSCI) (CSCI.TO), a specialty biopharmaceutical company, has an upcoming clinical trial readout for Macimorelin that is worth monitoring this quarter.
Macimorelin, an oral drug was approved by the FDA in December 2017 and by the European Commission in January 2019 for the diagnosis of adult growth hormone deficiency (AGHD), a condition where the patient does not have enough growth hormone. It is not used to treat patients with the condition. Macimorelin is approved for marketing under the brand name GHRYVELIN in the European Economic Area and as Macrilen in the United States, South Korea and Israel.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.